8-K: STRATA Skin Sciences Reports Mixed Q1 2024 Results Amid Strategic Shift

STRATA Skin Sciences reported a decrease in revenue for the first quarter of 2024, but showed signs of improvement in recurring billings and reduced operating expenses.

Summary

• STRATA Skin Sciences announced its financial results for the first quarter of 2024, showing a revenue of $6.8 million, which is an 11% decrease compared to the $7.6 million in the same quarter of 2023.
• Global net recurring revenue also declined by 10% year-over-year to $4.7 million, down from $5.2 million in the first quarter of 2023, impacted by deferred billings.
• However, gross domestic recurring billings saw a smaller year-over-year decline of 3%, totaling $4.6 million, which is an improvement from the double-digit declines in the previous three quarters.
• Operating expenses decreased by 14% year-over-year to $6.0 million, down from $7.0 million in the first quarter of 2023.
• The company's net loss for the quarter was $3.4 million, or $0.10 per share, compared to a net loss of $2.8 million, or $0.08 per share, in the first quarter of 2023.
• STRATA's domestic installed base includes 907 XTRAC devices and 104 TheraClearX devices as of March 31, 2024.
• The company has renewed 3-year agreements with exclusive distributors in China and Japan, which include minimum unit placements and/or purchases of XTRAC and VTRAC devices.
• STRATA also amended its credit agreement with MidCap Financial Trust to refinance existing debt and support future business needs.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the revenue decline and increased net loss, although there are some positive signs of improvement in recurring billings and cost management. The company's future outlook is dependent on successful execution of its strategy.

Positives

• The decline in gross domestic recurring billings slowed to 3%, a significant improvement from double-digit declines in the prior three quarters, indicating a potential turnaround.
• Operating expenses decreased by 14% year-over-year, showing improved cost management.
• The company reduced its cash burn by $1.1 million compared to the same quarter last year.
• STRATA renewed 3-year agreements with exclusive distributors in China and Japan, securing future international revenue.
• The company is actively working to broaden CPT code coverage to increase patient access and provider reimbursement.
• TheraClearX has demonstrated significant efficacy in reducing acne lesions.

Negatives

• Overall revenue decreased by 11% year-over-year to $6.8 million.
• Global net recurring revenue decreased by 10% year-over-year to $4.7 million.
• The company reported a net loss of $3.4 million, or $0.10 per share, for the quarter.
• The domestic installed base of XTRAC devices decreased from 923 to 907, as the company realigns assets and removes underperforming accounts.
• Gross profit decreased to $3.1 million, or 46% of revenue, compared to $4.4 million, or 58% of revenue, in the first quarter of 2023.

Risks

• The company is still experiencing a decline in overall revenue and recurring revenue.
• The net loss for the quarter increased compared to the same period last year.
• The decrease in the installed base of XTRAC devices could impact future revenue.
• The company's success depends on the execution of its new go-to-market strategies and international expansion plans.
• The company's ability to reach breakeven and become cash flow positive is dependent on successful execution of its multifaceted strategy.

Future Outlook

The company aims to increase XTRAC device utilization and recurring revenue per device through direct-to-consumer efforts and repositioning of devices. They also plan to grow the installed base and utilization of TheraClearX devices and continue international expansion. The company believes it can reach breakeven and be cash flow positive if it successfully executes its strategy.

Management Comments

• The 3.3% year-over-year decline in gross domestic recurring billings in the first quarter of 2024 was the smallest decline in this year-over-year metric since the end of the second quarter of 2022.
• This performance points to signs of a trough in our domestic business, even as we reduced our cash burn by $1.1 million and our operating expenses by $1.0 million in this year's first quarter compared to a year ago.
• Our strategic focus is on increasing XTRAC device utilization and recurring revenue per device, primarily through increased DTC efforts and the repositioning of some XTRAC devices from underperforming accounts to accounts with better potential.
• If we can successfully execute on our multifaceted strategy, we believe we can reach breakeven and be cash flow positive.

Industry Context

The medical technology industry is competitive, and STRATA's focus on recurring revenue models and international expansion aligns with trends in the sector. The company's efforts to broaden CPT code coverage are also relevant in the context of healthcare reimbursement challenges.

Comparison to Industry Standards

• Comparing STRATA's performance to companies like Cutera and Cynosure, which also operate in the medical aesthetics and dermatology space, reveals that STRATA's revenue decline is concerning, as these companies have shown more stable or growing revenue streams.
• While Cutera and Cynosure have a broader product portfolio, STRATA's focus on recurring revenue through its partnership program is a unique approach, but the current results indicate that this model is not yet delivering the expected growth.
• The reduction in operating expenses is a positive step, but the company needs to demonstrate that it can achieve revenue growth to justify its valuation.
• The company's international expansion efforts are similar to those of its competitors, but the success of these efforts will depend on effective execution and market penetration.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and increased net loss.
• Employees may be affected by the company's strategic shift and cost management efforts.
• Customers may benefit from the company's focus on improving treatment access and efficacy.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors may be reassured by the company's debt refinancing and cost reduction efforts.

Next Steps

• The company will focus on increasing XTRAC device utilization and recurring revenue per device.
• STRATA will continue to grow the installed base and utilization of TheraClearX devices.
• The company will execute on its international expansion plans with its XTRAC devices.
• STRATA will continue its outreach initiative focused on broadening CPT code coverage.

Key Dates

Keywords

STRATA Skin Sciences, XTRAC, TheraClearX, dermatology, medical technology, recurring revenue, financial results, acne treatment, psoriasis, vitiligo